IMMU Stock Overview
A biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Mendus AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr10.14 |
52 Week High | kr28.40 |
52 Week Low | kr6.00 |
Beta | 0.97 |
1 Month Change | 6.85% |
3 Month Change | 3.58% |
1 Year Change | -64.30% |
3 Year Change | -89.59% |
5 Year Change | -93.65% |
Change since IPO | -94.04% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Mendus' (STO:IMMU) Cash Burn Rate
Feb 20Mendus (STO:IMMU) Is Making Moderate Use Of Debt
Mar 28Is Mendus (STO:IMMU) Using Debt Sensibly?
Dec 01Is Mendus (STO:IMMU) Using Debt Sensibly?
Aug 10Health Check: How Prudently Does Immunicum (STO:IMMU) Use Debt?
May 10Is Immunicum (STO:IMMU) Using Too Much Debt?
Jan 31Shareholder Returns
IMMU | SE Biotechs | SE Market | |
---|---|---|---|
7D | 6.3% | 2.0% | -0.9% |
1Y | -64.3% | 10.1% | 14.2% |
Return vs Industry: IMMU underperformed the Swedish Biotechs industry which returned 9.5% over the past year.
Return vs Market: IMMU underperformed the Swedish Market which returned 14.3% over the past year.
Price Volatility
IMMU volatility | |
---|---|
IMMU Average Weekly Movement | 6.6% |
Biotechs Industry Average Movement | 9.0% |
Market Average Movement | 5.9% |
10% most volatile stocks in SE Market | 12.9% |
10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: IMMU has not had significant price volatility in the past 3 months.
Volatility Over Time: IMMU's weekly volatility has decreased from 15% to 7% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 30 | Erik Manting | www.mendus.com |
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which completed Phase I clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a preclinical study for NK cell-based therapies.
Mendus AB (publ) Fundamentals Summary
IMMU fundamental statistics | |
---|---|
Market cap | kr510.65m |
Earnings (TTM) | -kr107.06m |
Revenue (TTM) | kr30.99m |
16.5x
P/S Ratio-4.8x
P/E RatioIs IMMU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IMMU income statement (TTM) | |
---|---|
Revenue | kr30.99m |
Cost of Revenue | kr0 |
Gross Profit | kr30.99m |
Other Expenses | kr138.05m |
Earnings | -kr107.06m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 23, 2024
Earnings per share (EPS) | -2.13 |
Gross Margin | 100.00% |
Net Profit Margin | -345.53% |
Debt/Equity Ratio | 0.1% |
How did IMMU perform over the long term?
See historical performance and comparison